Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LNTH
Strong BuyAPPROVELantheus Holdings, Inc. · Healthcare · United States · $6.6B · Avg Vol: $179M/d
Lantheus Holdings makes diagnostic radiopharmaceuticals, notably a prostate cancer imaging agent and a cardiac imaging product, generating strong cash flow with a good quality score (Q75) and strong momentum (M78). Nothing adverse is known on accounting, solvency or governance.
COMPANY DESCRIPTION
Lantheus Holdings, Inc. is a radiopharmaceutical company focused on developing, manufacturing, and commercializing innovative diagnostic and therapeutic products for medical imaging. It is a specialized leader in medical diagnostics, particularly in cardiology and oncology imaging agents, benefiting from proprietary technologies and regulatory approvals. Its pipeline of novel agents and established market presence provide a strong competitive moat in a high-barrier-to-entry market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 935.1M | 1.3B | 1.5B | 1.5B | 18.1% | 1.6B | 1.5B | 1.6B | 3.4% |
| EPS | 0.41 | 4.79 | 4.52 | 3.46 | 103.6% | 4.18 | 3.19 | 3.60 | 2.0% |
| Shares | 67.5M | 68.5M | 68.5M | 64.6M | -4.3% | 65.3M | — | — | — |
| Debt | 583.5M | 616.9M | 619.4M | 619.4M | 2.0% | 625.0M | — | — | — |
| Equity | 447.1M | 815.9M | 1.1B | 1.1B | 34.6% | — | — | — | — |
| Op CF | 281.8M | 305.3M | 544.8M | 390.1M | 11.5% | 412.8M | — | — | — |
| Inv CF | -276.5M | 5.9M | -226.0M | -627.2M | — | — | — | — | — |
| Fin CF | 311.7M | -13.1M | -118.5M | -316.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LNTH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LNTH | Lantheus Holdings, Inc.(you) | $6.6B | 87 | Strong Buy |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.1B | 84 | Strong Buy |
| INDV | Indivior Pharmaceuticals, Inc. | $4.1B | 94 | Strong Buy |
| LQDA | Liquidia Corporation | $6.1B | 70 | Buy |
| NBIX | Neurocrine Biosciences, Inc. | $15.7B | 84 | Strong Buy |
| VIA.DE | Viatris Inc. | $18.8B | 87 | Strong Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.5B | 89 | Strong Buy |
| TRLV | Trulieve Cannabis Corp. | $2.3B | 90 | Strong Buy |
| UTHR | United Therapeutics Corporation | $22.1B | 87 | Strong Buy |
| ELAN | Elanco Animal Health Incorporated | $12.0B | 69 | Buy |
Peer medians: ROE -25.9% · P/E 29.6x · Gross margin 58.7%